Real-Options Valuation for a Biotechnology Company

Financial Analysts Journal

Volumn 56, Issue 3, 2000, Pages 76-84

  Kellog, David ^a   Charnes, John M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001954909     PISSN: 0015198X     EISSN: None     Source Type: Journal    
DOI: 10.2469/faj.v56.n3.2362     Document Type: Article

References (11)

1. Amram, M., and N. Kulatilaka. 1998. Real Options: Managing Strategic Investment in an Uncertain World. Boston, MA: Harvard Business School Press.
2. Copeland, T. 1998. "A Practitioner's View of Applications of Real Options." Second Annual Conference on Real Options, Chicago, IL (June).
3. Cox, J., S. Ross, and M. Rubinstein. 1979. "Option Pricing: A Simplified Approach." Journal of Financial Economics, vol. 7 (September):229-263.
4. DiMasi, J.A., R.W. Hansen, H.G. Grabowski, and L. Lasagna. 1991. "Cost of Innovation in the Pharmaceutical Industry." Journal of Health Economics, vol. 10, no. 2:107-142.
5. Grabowski, H.G., and J.M. Vernon. 1994. "Returns to R&D on New Drug Introductions in the 1980s." Journal of Health Economics, vol. 13:383-406.
6. Kasanen, E., and L. Trigeorgis. 1994. "A Market Utility Approach to Investment Valuation." European Journal of Operational Research, vol. 74:294-309.
7. Mason, S.P., and R.C. Merton. 1983. "The Role of Contingent Claims Analysis in Corporate Finance." In Recent Advances in Corporate Finance. Edited by E. Altman. Chicago, IL: Irwin.
8. Myers, S.C., and C.D. Howe. 1997. "A Life-Cycle Financial Model of Pharmaceutical R&D." Program on the Pharmaceutical Industry, Massachusetts Institute of Technology.
9. Myers, S.C., and L. Shyam-Sunder. 1996. "Measuring Pharmaceutical Industry Risk and the Cost of Capital." In Competitive Strategies in the Pharmaceutical Industry. Edited by Robert B. Helms. Washington, DC: American Enterprise Institute Press.
10. Trigeorgis, L. 1997. "Real Options, Managerial Flexibility and Strategy in Resovirce Allocation," Cambridge, MA: MIT Press.
11. U.S. Congress, Office of Technology Assessment. 1993. Pharmaceutical R&D: Costs, Risks, and Rewards, OTA-H-522. Washington, DC: U.S. Government Printing Office (February).